ERBB2 and non-small cell lung carcinoma: Preclinical evidence suggests that combining osimertinib with the anti-EGFR antibody cetuximab and the anti-HER2 antibody trastuzumab overcomes and prevents resistance to first- or second-line osimertinib in cell-line- and patient-derived xenograft models of EGFR-mutated NSCLC [154,155].